Caris Life Sciences Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Caris Life Sciences, Inc. , a leading, patient centric, next-generation AI TechBio company, today reported financial results for the quarter ended September 30, ...
New data reveals differences in gene activity in the brains of men and women. They start in the womb and evolved millions of ...
Researchers at Karolinska Institutet and Yale University have created a multidimensional, molecular map of how the mouse ...
19hon MSN
Veracyte raises 2025 revenue outlook to $510M while accelerating double-digit growth investments
Q3 2025 Management View Marc Stapley, CEO, highlighted "another outstanding quarter" with core testing business revenue up 18% year-over-year after adjusting for Envisia, supported by 26% volume ...
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new results from the ongoing real-world FLEX Study (NCT03053193) at the 2025 San Antonio Breast Cancer ...
Cash and Cash Equivalents: As of September 30, 2025, Kymera had $978.7 million in cash, cash equivalents and investments. Kymera expects that its cash balance will provide the Company with a cash ...
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating the Afirma GRID (Genomic Resource for Intelligent Discovery) research ...
A new research paper featured on the cover of Volume 17, Issue 10 of Aging-US was published on October 20, 2025, titled ...
One in four adults over the age of 25 will have a stroke in a lifetime, according to the Global Stroke Fact Sheet 2025.
African umbrella acacia trees grow more during droughts, contrasting with the conservative splendid thorn acacia, a study in The Plant Journal shows.
This study presents valuable findings on the role of KLF6 in in vitro endothelial cells exposed to altered (high or low) shear stress with a customized microfluidic device to investigate mechanisms of ...
Celltrion Inc. announced Oct. 29 the signing of an $87.75 million joint drug R&D agreement with AI and spatial transcriptome-based biotech Portrai Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results